Search for other papers by Yoon Young Cho in
Google Scholar
PubMed
Search for other papers by Hye Won Jang in
Google Scholar
PubMed
Search for other papers by Ji Young Joung in
Google Scholar
PubMed
Search for other papers by Sun-Mi Park in
Google Scholar
PubMed
Search for other papers by Dae Joon Jeong in
Google Scholar
PubMed
Search for other papers by Sun Wook Kim in
Google Scholar
PubMed
Search for other papers by Jae Hoon Chung in
Google Scholar
PubMed
Introduction Childhood thyroid cancer is a rare malignancy, but its incidence has been gradually increasing according to several epidemiologic studies [ 1 , 2 ]. An increase in the incidence of childhood thyroid cancer (aged 0-14 years) was
Search for other papers by Rima Bėrontienė in
Google Scholar
PubMed
Search for other papers by Edita Jašinskienė in
Google Scholar
PubMed
Search for other papers by Rosita Kiudelienė in
Google Scholar
PubMed
Search for other papers by Gintaras Kuprionis in
Google Scholar
PubMed
Search for other papers by Jurgita Makštienė in
Google Scholar
PubMed
Search for other papers by Raminta Macaitytė in
Google Scholar
PubMed
Search for other papers by Dalia Marčiulionytė in
Google Scholar
PubMed
Search for other papers by Lina Poškienė in
Google Scholar
PubMed
Search for other papers by Agnė Šemetaitė in
Google Scholar
PubMed
Search for other papers by Vygantas Šidlauskas in
Google Scholar
PubMed
Search for other papers by Raimondas Valickas in
Google Scholar
PubMed
Search for other papers by Rimantas Žalinkevičius in
Google Scholar
PubMed
Institute of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania
Search for other papers by Rasa Verkauskienė in
Google Scholar
PubMed
-90% in adults [ 5 ]. A decade after the Chernobyl accident in 1986, the incidence of TC in children had increased dramatically, especially in the most radiation-contaminated areas of Belarus, Ukraine and Russia [ 6 ]. The Chernobyl accident demonstrated
Search for other papers by Ladan Mehran in
Google Scholar
PubMed
Search for other papers by Atieh Amouzegar in
Google Scholar
PubMed
Search for other papers by Hengameh Abdi in
Google Scholar
PubMed
Search for other papers by Negar Delbari in
Google Scholar
PubMed
Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
Search for other papers by Elham Madreseh in
Google Scholar
PubMed
Search for other papers by Maryam Tohidi in
Google Scholar
PubMed
Search for other papers by Mohammad Ali Mansournia in
Google Scholar
PubMed
Search for other papers by Fereidoun Azizi in
Google Scholar
PubMed
individuals with and without MetS as well as evaluating the incidence of TD and trend of thyroid hormones according to the MetS group, during a 10 year follow-up in an iodine sufficient population. Materials and Methods Study Design TTS is a
Search for other papers by Santiago Tofé in
Google Scholar
PubMed
Search for other papers by Iñaki Argüelles in
Google Scholar
PubMed
Search for other papers by Ana Forteza in
Google Scholar
PubMed
Search for other papers by Cristina Álvarez in
Google Scholar
PubMed
Search for other papers by Alessandra Repetto in
Google Scholar
PubMed
Search for other papers by Luis Masmiquel in
Google Scholar
PubMed
Search for other papers by Irene Rodríguez in
Google Scholar
PubMed
Search for other papers by Eladio Losada in
Google Scholar
PubMed
Search for other papers by Nuria Sukunza in
Google Scholar
PubMed
Search for other papers by María Cabrer in
Google Scholar
PubMed
Search for other papers by Mildred Sifontes in
Google Scholar
PubMed
Search for other papers by María del Mar del Barrio in
Google Scholar
PubMed
Search for other papers by Antonia Barceló in
Google Scholar
PubMed
Search for other papers by Álvaro Tofé in
Google Scholar
PubMed
Search for other papers by Vicente Pereg in
Google Scholar
PubMed
Introduction Thyroid cancer (TC) represents 3% of the global incidence of all cancers, with 586,000 new patients estimated in 2020 worldwide ( https://gco.iarc.fr/today/home ). It is the most frequent endocrine cancer and its global incidence
Search for other papers by Jeppe Lerche la Cour in
Google Scholar
PubMed
Search for other papers by Line Tang Møllehave in
Google Scholar
PubMed
Search for other papers by Bjarke Røssner Medici in
Google Scholar
PubMed
Search for other papers by Christian Zinck Jensen in
Google Scholar
PubMed
Search for other papers by Anne Ahrendt Bjerregaard in
Google Scholar
PubMed
Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Birte Nygaard in
Google Scholar
PubMed
Introduction
High compared with low educational level increases the odds of starting levothyroxine (L-T4) with a normal thyroid-stimulating hormone – the mechanism is most likely patient request. The use of liothyronine (L-T3) and desiccated thyroid extract (DTE) is also speculated to be initiated at patients’ request. Therefore, the primary aim of this study was to evaluate if educational level influences treatment with L-T3 and DTE.
Material and methods
In this register-based cross-sectional study, we included all Danish citizens ≥30 years with redeemed prescription of L-T4, L-T3, or DTE during 2017–2020. We defined educational levels as short, medium, and long (<10 years, 10–12 years, and above 12 years, respectively). The association between educational level and treatment with LT3 or DTE vs only LT4 was analyzed in logistic regression models adjusted for age and sex.
Results
We included 154,360 individuals using thyroid medication of whom 3829 were treated with L-T3 (2.48%) and 430 with DTE (0.28%). The usage was highest among women (3.15%) and the age group 40–49 (5.6%). Longer education compared with short increased the odds of being treated with DTE or L-T3 (medium education odds ratio (OR) 1.61 (95% CI 1.50–1.8) and long education OR 1.95 (95% CI 1.79–2.13)). Test for trend: OR: 1.37 (95% CI 1.31–1.42). Adjustment for other covariates did not affect the results substantially.
Conclusion
Persons with a longer compared to a shorter education are more often treated with either DTE or L-T3, and the usage of these drugs is limited to less than 3% of thyroid hormone users.
Search for other papers by Kanhaiyalal Agrawal in
Google Scholar
PubMed
Search for other papers by James Weaver in
Google Scholar
PubMed
Departments of Clinical PET Centre, King's College London, London, UK
Search for other papers by Fahim Ul-Hassan in
Google Scholar
PubMed
Search for other papers by Jean-Pierre Jeannon in
Google Scholar
PubMed
Search for other papers by Ricard Simo in
Google Scholar
PubMed
Search for other papers by Paul Carroll in
Google Scholar
PubMed
Search for other papers by Johnathan G. Hubbard in
Google Scholar
PubMed
Search for other papers by Ashish Chandra in
Google Scholar
PubMed
Departments of Clinical PET Centre, King's College London, London, UK
Search for other papers by Hosahalli Krishnamurthy Mohan in
Google Scholar
PubMed
of thyroid incidentalomas on 18 F-FDG PET varies from 0.2 to 10.1% in different studies [ 4 ]. This could well be related to variation in geographic area, number of patients studied and patient characteristics. The incidence of malignant neoplasm
Search for other papers by Brigitte Decallonne in
Google Scholar
PubMed
Search for other papers by Annick Van den Bruel in
Google Scholar
PubMed
Search for other papers by Gilles Macq in
Google Scholar
PubMed
Search for other papers by Nathalie Elaut in
Google Scholar
PubMed
Search for other papers by Harlinde De Schutter in
Google Scholar
PubMed
Introduction In Belgium, higher thyroid cancer incidence – most pronounced for microcancers (T1a) – is present in the Southern region, Wallonia, compared to the Northern region, Flanders. In a pioneer national population
Diabetes and Metabolism Research Unit, Vall Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Barcelona, Spain
Search for other papers by Carles Zafon in
Google Scholar
PubMed
Search for other papers by Juan Antonio Baena in
Google Scholar
PubMed
Search for other papers by Josep Castellví in
Google Scholar
PubMed
Diabetes and Metabolism Research Unit, Vall Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Barcelona, Spain
Search for other papers by Gabriel Obiols in
Google Scholar
PubMed
Search for other papers by Oscar Gonzalez in
Google Scholar
PubMed
Search for other papers by José Manuel Fort in
Google Scholar
PubMed
Search for other papers by Ramon Vilallonga in
Google Scholar
PubMed
Search for other papers by Enric Caubet in
Google Scholar
PubMed
Search for other papers by Manuel Armengol in
Google Scholar
PubMed
Diabetes and Metabolism Research Unit, Vall Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Barcelona, Spain
Search for other papers by Jordi Mesa in
Google Scholar
PubMed
Introduction Numerous studies have shown a worldwide increase in the incidence of thyroid cancer (TC) in recent years [ 1 ] due to the increased frequency of papillary thyroid carcinoma (PTC). The reason for this increase is not well
Search for other papers by Diana Borges Duarte in
Google Scholar
PubMed
Search for other papers by Vânia Benido Silva in
Google Scholar
PubMed
Search for other papers by Guilherme Assunção in
Google Scholar
PubMed
Search for other papers by André Couto Carvalho in
Google Scholar
PubMed
Search for other papers by Cláudia Freitas in
Google Scholar
PubMed
Introduction Differentiated thyroid carcinoma (DTC) is the most common endocrine gland malignancy, most frequently diagnosed among women between the ages of 45 and 54 years ( 1 , 2 ). Despite the increasing incidence worldwide over the last
Search for other papers by Emilie Sonne-Holm in
Google Scholar
PubMed
Search for other papers by Christoffer Holst Hahn in
Google Scholar
PubMed
asymptomatic and self-limiting but can also lead to hypocalcaemia with symptoms of paraesthesia and muscle spasms manifesting within the first 24 h after surgery [ 14 ]. The incidence of complication varying from 1 to 50% [ 3 , 10 , 14 - 16 ] is in part